Sensitive skin and allergy related skin conditions have become increasingly prevalent, intensifying the need for reliable, ethically responsible and clinically meaningful approaches to assess product safety and to substantiate hypoallergenic product claims. Traditional models like the HRIPT face significant ethical and scientific limitations, including the intentional induction of sensitisation and low real-world relevance. Dermatest’s HypoSense^® offers a modern alternative through a structured approach combining strict ingredient screening, a standardized patch test and a four-week Safety-In-Use study in a highly sensitive test population. The method provides reproducible, clinically meaningful data and reflects real-life usage conditions. Overall, HypoSense^® provides a robust state of the art framework for substantiating hypoallergenic claims, ensuring maximum consumer safety and ethical compliance while strengthening consumer trust in dermatological safety declarations.